{"id":"https://openalex.org/W4396599772","doi":"https://doi.org/10.1158/1538-7445.sabcs23-ps12-08","title":"Abstract PS12-08: MORPHEUS Hormone Receptor-Positive Breast Cancer: interim analysis of a Phase Ib/II, study of fulvestrant \u00b1 atezolizumab and abemaciclib triplet treatment in patients metastatic disease","display_name":"Abstract PS12-08: MORPHEUS Hormone Receptor-Positive Breast Cancer: interim analysis of a Phase Ib/II, study of fulvestrant \u00b1 atezolizumab and abemaciclib triplet treatment in patients metastatic disease","publication_year":2024,"publication_date":"2024-05-02","ids":{"openalex":"https://openalex.org/W4396599772","doi":"https://doi.org/10.1158/1538-7445.sabcs23-ps12-08"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.sabcs23-ps12-08","doi":"https://doi.org/10.1158/1538-7445.sabcs23-ps12-08","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs23-ps12-08","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5049348377","display_name":"Kyung Hae Jung","orcid":"https://orcid.org/0000-0002-1580-7224","observed_orcids":["https://orcid.org/0000-0002-1580-7224"]},"institutions":[{"id":"https://openalex.org/I2801680663","display_name":"Asan Medical Center","ror":"https://ror.org/03s5q0090","country_code":"KR","type":"healthcare","lineage":["https://openalex.org/I2801680663","https://openalex.org/I4210167194"]},{"id":"https://openalex.org/I40542001","display_name":"University of Ulsan","ror":"https://ror.org/02c2f8975","country_code":"KR","type":"education","lineage":["https://openalex.org/I40542001"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Kyung Hae Jung","raw_affiliation_strings":["1Asan Medical Center, University of Ulsan College of Medicine, Republic of Korea;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Asan Medical Center, University of Ulsan College of Medicine, Republic of Korea;","institution_ids":["https://openalex.org/I2801680663","https://openalex.org/I40542001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069050806","display_name":"Seock\u2010Ah Im","orcid":"https://orcid.org/0000-0002-5396-6533","observed_orcids":["https://orcid.org/0000-0002-5396-6533"]},"institutions":[{"id":"https://openalex.org/I139264467","display_name":"Seoul National University","ror":"https://ror.org/04h9pn542","country_code":"KR","type":"education","lineage":["https://openalex.org/I139264467"]},{"id":"https://openalex.org/I2802835388","display_name":"Seoul National University Hospital","ror":"https://ror.org/01z4nnt86","country_code":"KR","type":"healthcare","lineage":["https://openalex.org/I139264467","https://openalex.org/I2802835388"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Seock-Ah Im","raw_affiliation_strings":["2Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Republic of Korea;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Republic of Korea;","institution_ids":["https://openalex.org/I139264467","https://openalex.org/I2802835388"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022422153","display_name":"Denise Aysel Yardley","orcid":"https://orcid.org/0000-0002-8664-3458","observed_orcids":["https://orcid.org/0000-0002-8664-3458","https://orcid.org/0009-0008-1720-6183"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Denise Yardley","raw_affiliation_strings":["3Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN, United States;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN, United States;","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068059897","display_name":"Sara Alsterlind Hurvitz","orcid":"https://orcid.org/0000-0001-7808-7191","observed_orcids":["https://orcid.org/0000-0001-7808-7191"]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sara Hurvitz","raw_affiliation_strings":["4Fred Hutchinson Cancer Center, Seattle, WA, United States;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Fred Hutchinson Cancer Center, Seattle, WA, United States;","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038366277","display_name":"Keun Seok Lee","orcid":"https://orcid.org/0000-0001-5575-836X","observed_orcids":["https://orcid.org/0000-0001-5575-836X"]},"institutions":[{"id":"https://openalex.org/I4210120052","display_name":"National Cancer Center","ror":"https://ror.org/02tsanh21","country_code":"KR","type":"healthcare","lineage":["https://openalex.org/I1290491151","https://openalex.org/I2801339556","https://openalex.org/I4210120052"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Keun Seok Lee","raw_affiliation_strings":["5Center for Breast Cancer, National Cancer Center, Republic of Korea;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Center for Breast Cancer, National Cancer Center, Republic of Korea;","institution_ids":["https://openalex.org/I4210120052"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002724338","display_name":"Amir Sonnenblick","orcid":"https://orcid.org/0000-0003-1954-4633","observed_orcids":["https://orcid.org/0000-0003-1954-4633"]},"institutions":[{"id":"https://openalex.org/I16391192","display_name":"Tel Aviv University","ror":"https://ror.org/04mhzgx49","country_code":"IL","type":"education","lineage":["https://openalex.org/I16391192"]},{"id":"https://openalex.org/I2799807261","display_name":"Tel Aviv Sourasky Medical Center","ror":"https://ror.org/04nd58p63","country_code":"IL","type":"healthcare","lineage":["https://openalex.org/I2799807261"]}],"countries":["IL"],"is_corresponding":false,"raw_author_name":"Amir Sonnenblick","raw_affiliation_strings":["6Oncology Division, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Israel;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Oncology Division, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Israel;","institution_ids":["https://openalex.org/I16391192","https://openalex.org/I2799807261"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047547446","display_name":"Shlomit Strulov Shachar","orcid":"https://orcid.org/0000-0002-3396-8419","observed_orcids":["https://orcid.org/0000-0002-3396-8419"]},"institutions":[{"id":"https://openalex.org/I16391192","display_name":"Tel Aviv University","ror":"https://ror.org/04mhzgx49","country_code":"IL","type":"education","lineage":["https://openalex.org/I16391192"]}],"countries":["IL"],"is_corresponding":false,"raw_author_name":"Shlomit Shachar","raw_affiliation_strings":["7Tel Aviv University, Israel;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Tel Aviv University, Israel;","institution_ids":["https://openalex.org/I16391192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022891785","display_name":"Antoinette R. Tan","orcid":"https://orcid.org/0000-0002-7895-7000","observed_orcids":["https://orcid.org/0000-0002-7895-7000"]},"institutions":[{"id":"https://openalex.org/I4210100342","display_name":"Levine Cancer Institute","ror":"https://ror.org/0174nh398","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334069289","https://openalex.org/I4210100342"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Antoinette Tan","raw_affiliation_strings":["8Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, United States;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"8Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, United States;","institution_ids":["https://openalex.org/I4210100342"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009038938","display_name":"Elizabeth Anne Comen","orcid":"https://orcid.org/0000-0002-9179-0399","observed_orcids":["https://orcid.org/0000-0002-9179-0399"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elizabeth Comen","raw_affiliation_strings":["9MSKCC;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"9MSKCC;","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084357214","display_name":"Einav Nili Gal\u2010Yam","orcid":"https://orcid.org/0000-0003-1059-7923","observed_orcids":["https://orcid.org/0000-0003-1059-7923"]},"institutions":[{"id":"https://openalex.org/I2799810450","display_name":"Sheba Medical Center","ror":"https://ror.org/020rzx487","country_code":"IL","type":"healthcare","lineage":["https://openalex.org/I2799810450"]}],"countries":["IL"],"is_corresponding":false,"raw_author_name":"Einav Gal-Yam","raw_affiliation_strings":["10Breast Oncology Institute Sheba Medical Center;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"10Breast Oncology Institute Sheba Medical Center;","institution_ids":["https://openalex.org/I2799810450"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044108002","display_name":"Adam Brufsky","orcid":"https://orcid.org/0000-0001-8080-7960","observed_orcids":["https://orcid.org/0000-0001-8080-7960","https://orcid.org/0009-0006-2725-3579"]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]},{"id":"https://openalex.org/I4210134769","display_name":"University of Pittsburgh Medical Center","ror":"https://ror.org/04ehecz88","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210098814","https://openalex.org/I4210134769"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Adam Brufsky","raw_affiliation_strings":["11UPMC Hillman Cancer Center, University of Pittsburgh Medical Center;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"11UPMC Hillman Cancer Center, University of Pittsburgh Medical Center;","institution_ids":["https://openalex.org/I4210128526","https://openalex.org/I4210134769"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090188675","display_name":"Hope S. Rugo","orcid":"https://orcid.org/0000-0001-6710-4814","observed_orcids":["https://orcid.org/0000-0001-6710-4814"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]},{"id":"https://openalex.org/I4210167126","display_name":"UCSF Helen Diller Family Comprehensive Cancer Center","ror":"https://ror.org/05yndxy10","country_code":"US","type":"facility","lineage":["https://openalex.org/I180670191","https://openalex.org/I4210110664","https://openalex.org/I4210167126"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hope Rugo","raw_affiliation_strings":["12Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, United States;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"12Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, United States;","institution_ids":["https://openalex.org/I180670191","https://openalex.org/I4210167126"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100317529","display_name":"Jing Fei Zhu","orcid":"https://orcid.org/0000-0002-1777-5262","observed_orcids":["https://orcid.org/0000-0002-1777-5262"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jing Zhu","raw_affiliation_strings":["13Genentech, Inc., South San Francisco, CA, United States;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"13Genentech, Inc., South San Francisco, CA, United States;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038315593","display_name":"Kelly DuPree","orcid":"https://orcid.org/0009-0006-2747-3918","observed_orcids":["https://orcid.org/0009-0006-2747-3918"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kelly DuPree","raw_affiliation_strings":["13Genentech, Inc., South San Francisco, CA, United States;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"13Genentech, Inc., South San Francisco, CA, United States;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033925325","display_name":"Vanessa L. Breton","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vanessa Breton","raw_affiliation_strings":["14F. Hoffmann-La Roche Ltd, Canada;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"14F. Hoffmann-La Roche Ltd, Canada;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014049666","display_name":"Fiona M. Young","orcid":"https://orcid.org/0009-0002-6405-5070","observed_orcids":["https://orcid.org/0009-0002-6405-5070"]},"institutions":[{"id":"https://openalex.org/I4210113058","display_name":"Roche (United Kingdom)","ror":"https://ror.org/024tgbv41","country_code":"GB","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I4210113058"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Fiona Young","raw_affiliation_strings":["15Roche Products Ltd, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"15Roche Products Ltd, United Kingdom;","institution_ids":["https://openalex.org/I4210113058"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009930268","display_name":"Richard B. Schwab","orcid":"https://orcid.org/0000-0002-0488-1226","observed_orcids":["https://orcid.org/0000-0002-0488-1226"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Richard Schwab","raw_affiliation_strings":["13Genentech, Inc., South San Francisco, CA, United States;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"13Genentech, Inc., South San Francisco, CA, United States;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034692104","display_name":"Edward Cha","orcid":"https://orcid.org/0000-0001-8172-0656","observed_orcids":["https://orcid.org/0000-0001-8172-0656"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Edward Cha","raw_affiliation_strings":["13Genentech, Inc., South San Francisco, CA, United States;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"13Genentech, Inc., South San Francisco, CA, United States;","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5052487618","display_name":"Melinda L. Telli","orcid":"https://orcid.org/0000-0001-7993-1235","observed_orcids":["https://orcid.org/0000-0001-7993-1235"]},"institutions":[{"id":"https://openalex.org/I4210137306","display_name":"Stanford Medicine","ror":"https://ror.org/03mtd9a03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Melinda Telli","raw_affiliation_strings":["16Stanford University School of Medicine, San Francisco, CA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"16Stanford University School of Medicine, San Francisco, CA, United States","institution_ids":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":20,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":8,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"84","issue":"9_Supplement","first_page":"PS12","last_page":"08"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/hormone-receptor-positive-breast-cancer","display_name":"hormone receptor-positive breast cancer","score":0.9779999852180481},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.9319999814033508},{"id":"https://openalex.org/keywords/fulvestrant","display_name":"fulvestrant","score":0.9380000233650208},{"id":"https://openalex.org/keywords/atezolizumab","display_name":"atezolizumab","score":0.9980000257492065},{"id":"https://openalex.org/keywords/abemaciclib","display_name":"abemaciclib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/cdk4-6-inhibitors","display_name":"CDK4/6 inhibitors","score":0.8859999775886536},{"id":"https://openalex.org/keywords/pd-l1","display_name":"PD-L1","score":0.7590000033378601},{"id":"https://openalex.org/keywords/immunotherapy","display_name":"immunotherapy","score":0.5149999856948853},{"id":"https://openalex.org/keywords/endocrine-resistance","display_name":"endocrine therapy resistance","score":0.8009999990463257},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.7200000286102295},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9800000190734863},{"id":"https://openalex.org/keywords/cd8-t-cell-infiltration","display_name":"CD8+ T cell infiltration","score":0.9020000100135803},{"id":"https://openalex.org/keywords/tumor-immune-microenvironment","display_name":"tumor immune microenvironment","score":0.550000011920929},{"id":"https://openalex.org/keywords/palbociclib","display_name":"palbociclib","score":0.7200000286102295},{"id":"https://openalex.org/keywords/triplet-therapy","display_name":"triplet therapy","score":0.3109999895095825}],"concepts":[{"id":"https://openalex.org/C2780482068","wikidata":"https://www.wikidata.org/wiki/Q5508491","display_name":"Fulvestrant","level":5,"score":0.9086247086524963},{"id":"https://openalex.org/C2775949291","wikidata":"https://www.wikidata.org/wiki/Q20707748","display_name":"Atezolizumab","level":5,"score":0.8247236013412476},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7328898906707764},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6409157514572144},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5859776139259338},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5017807483673096},{"id":"https://openalex.org/C61943457","wikidata":"https://www.wikidata.org/wiki/Q6046661","display_name":"Interim analysis","level":3,"score":0.494144469499588},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.484536349773407},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.45511797070503235},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.42827847599983215},{"id":"https://openalex.org/C84606932","wikidata":"https://www.wikidata.org/wiki/Q416496","display_name":"Estrogen receptor","level":4,"score":0.2714006304740906},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.1520419716835022},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.09911978244781494},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.08649832010269165}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.sabcs23-ps12-08","doi":"https://doi.org/10.1158/1538-7445.sabcs23-ps12-08","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs23-ps12-08","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2624659532","https://openalex.org/W4405539758","https://openalex.org/W3013711219","https://openalex.org/W2947864495","https://openalex.org/W2898116555","https://openalex.org/W7167524021","https://openalex.org/W2620993107","https://openalex.org/W3082381786","https://openalex.org/W2942192576","https://openalex.org/W4411290496"],"abstract_inverted_index":{"Abstract":[0],"BACKGROUND":[1],"Endocrine":[2],"therapy":[3,94,414],"(ET)":[4],"is":[5],"the":[6,49,237,262,276,290,303,328,341,431,474,592],"mainstay":[7],"of":[8,147,198,248,309,354,397,407,415,440,463,571,576,591],"treatment":[9,105,583],"for":[10,95,183,229],"metastatic":[11,77,96,252,586],"hormone":[12],"receptor-positive":[13],"breast":[14],"cancer":[15,29],"(HR+":[16],"BC).":[17],"ET":[18],"resistance":[19],"and":[20,69,103,169,191,203,208,223,255,295,363,399,402,424,458,477,580],"disease":[21,88,335,587],"progression":[22,89],"are":[23,31,259,325,461],"expected,":[24],"thus":[25],"novel":[26],"therapies,":[27],"like":[28],"immunotherapy,":[30],"needed.":[32],"Prior":[33],"data":[34,324],"suggest":[35],"that":[36,381],"abemaciclib":[37,581],"(abema),":[38],"a":[39,107,135,175,572],"cyclin-dependent":[40,497],"kinase":[41,498],"4/6":[42],"(CDK4/6)":[43],"inhibitor,":[44],"has":[45],"immunomodulatory":[46],"activity.":[47],"In":[48],"MORPHEUS":[50,564],"HR+":[51,76,101],"BC":[52,102],"study":[53,575],"(NCT03280563),":[54],"atezolizumab":[55,579],"(atezo;":[56],"anti\u2013programmed":[57],"death-ligand":[58],"1":[59],"[PD-L1])":[60],"was":[61,139,174,266,317,338,389,446,471],"tested":[62],"in":[63,72,164,261,275,289,302,327,340,375,430,473,480,584],"combination":[64,439],"with":[65,68,75,86,106,239,373,392,404,427,448],"fulvestrant":[66,577],"(FUL),":[67],"without":[70],"abema,":[71],"patients":[73,464,585],"(pts)":[74],"BC.":[78],"We":[79],"present":[80],"24-week":[81],"interim":[82,569],"analyses.":[83],"METHODS":[84],"Pts":[85,142,226],"measurable":[87],"during":[90],"first-":[91],"or":[92,97,116,126,150,433],"second-line":[93],"inoperable":[98],"locally":[99],"advanced":[100],"prior":[104,137,243,251],"CDK4/6":[108],"inhibitor":[109],"were":[110,143,155,181,212,227,234],"randomized":[111,213],"to":[112,214,383],"receive":[113],"FUL":[114,117,127,138,281,293,304,314,316,346,388,420,428,445],"(control)":[115],"+":[118,128,130,216,218,221,278,280,292,311,313,343,345,385,387,417,419,442,444],"atezo":[119,129,215,220,277,291,310,342,384,416,441],"(1200":[120],"mg":[121,133],"intravenous":[122],"every":[123],"3":[124],"weeks)":[125],"abema":[131,217,279,312,344,386,418,443],"(150":[132],"twice":[134],"day);":[136],"not":[140,371],"permitted.":[141],"treated":[144,472],"until":[145],"loss":[146],"clinical":[148],"benefit":[149],"unacceptable":[151],"toxicity.":[152],"Primary":[153],"endpoints":[154],"objective":[156,512],"response":[157,374,382,513],"rate":[158],"(ORR)":[159],"per":[160],"Response":[161],"Evaluation":[162],"Criteria":[163],"Solid":[165],"Tumours":[166],"(RECIST)":[167],"v1.1":[168],"safety.":[170],"Progression-free":[171],"survival":[172],"(PFS)":[173],"secondary":[176],"endpoint.":[177],"Baseline":[178],"tumor":[179,360],"samples":[180],"analyzed":[182],"PD-L1":[184,355],"expression":[185,193,395,406],"(SP263),":[186],"CD8":[187,364],"T":[188],"cell":[189],"infiltration,":[190],"gene":[192],"by":[194],"RNAseq.":[195],"RESULTS":[196],"As":[197],"Dec":[199,600],"2022,":[200],"40,":[201],"31,":[202],"25":[204],"pts":[205,241],"(38,":[206],"30,":[207],"20":[209],"evaluable":[210],"pts)":[211],"FUL,":[219,222,224],"respectively.":[225],"followed":[228],"\u2265":[230],"24":[231],"weeks.":[232],"Demographics":[233],"similar":[235],"among":[236],"groups,":[238],"most":[240],"receiving":[242],"palbociclib":[244],"(palbo)":[245],"as":[246],"part":[247],"their":[249],"only":[250],"therapy.":[253],"Details":[254],"best":[256],"confirmed":[257],"ORRs":[258],"shown":[260,326],"table.":[263,329],"Median":[264],"PFS":[265,425],"6.34":[267],"months":[268,284,297],"(95%":[269,285,298,319],"confidence":[270,501],"interval":[271],"[CI]":[272],"5.52,":[273],"16.03)":[274],"arm,":[282,294],"3.15":[283],"CI":[286,299,320],"1.51,":[287],"7.79)":[288],"1.95":[296],"1.45,":[300],"4.93)":[301],"arm.":[305,347,377],"The":[306,412],"hazard":[307],"ratio":[308],"vs":[315],"0.43":[318],"0.24,":[321],"0.78).":[322],"Safety":[323],"Mild/moderate":[330],"(grade":[331],"1/2)":[332],"interstitial":[333],"lung":[334],"(ILD)/pneumonitis":[336],"(7.7%)":[337],"observed":[339],"At":[348],"baseline,":[349],"tumors":[350],"exhibited":[351],"low":[352,393],"prevalence":[353],"(median":[356],"immune":[357,409],"cells:":[358,361],"0.5%,":[359],"0%)":[362],"infiltration":[365],"(12%":[366],"inflamed":[367],"phenotype),":[368],"which":[369],"did":[370],"associate":[372],"any":[376],"RNAseq":[378],"analysis":[379,570],"indicated":[380],"strongly":[390],"associated":[391],"baseline":[394],"levels":[396],"proliferation":[398],"metabolism":[400],"signatures":[401],"trended":[403],"high":[405],"some":[408],"signatures.":[410],"CONCLUSIONS":[411],"triplet":[413,582],"showed":[421],"improved":[422],"ORR":[423],"compared":[426],"monotherapy":[429],"second-":[432],"third-line":[434],"setting":[435],"post-CDK4/6":[436],"inhibitor.":[437],"This":[438],"tolerable,":[447],"no":[449,454],"unexpected":[450],"safety":[451,459],"signals,":[452],"including":[453],"high-grade":[455],"ILD/pneumonitis.":[456],"Efficacy":[457],"Data":[460],"number":[462],"(%),":[465],"unless":[466],"otherwise":[467],"specified.":[468],"*":[469],"Patient":[470],"second":[475],"line":[476],"incorrectly":[478],"included":[479],"this":[481],"group.":[482],"Abema,":[483],"abemaciclib;":[484],"AE,":[485],"adverse":[486,507,520],"event;":[487,508],"ALT,":[488],"alanine":[489],"aminotransferase;":[490,493],"AST,":[491],"aspartate":[492],"atezo,":[494],"atezolizumab;":[495],"CDK4/6,":[496],"4/6;":[499],"CI,":[500],"interval;":[502],"ful,":[503],"fulvestrant;":[504],"irAE,":[505],"immune-related":[506],"L,":[509],"line;":[510],"ORR,":[511],"rate;":[514],"PFS,":[515],"progression-free":[516],"survival;":[517],"TRAE,":[518],"treatment-related":[519],"event.":[521],"Citation":[522],"Format:":[523],"Kyung":[524],"Hae":[525],"Jung,":[526],"Seock-Ah":[527],"Im,":[528],"Denise":[529],"Yardley,":[530],"Sara":[531],"Hurvitz,":[532],"Keun":[533],"Seok":[534],"Lee,":[535],"Amir":[536],"Sonnenblick,":[537],"Shlomit":[538],"Shachar,":[539],"Antoinette":[540],"Tan,":[541],"Elizabeth":[542],"Comen,":[543],"Einav":[544],"Gal-Yam,":[545],"Adam":[546],"Brufsky,":[547],"Hope":[548],"Rugo,":[549],"Jing":[550],"Zhu,":[551],"Kelly":[552],"DuPree,":[553],"Vanessa":[554],"Breton,":[555],"Fiona":[556],"Young,":[557],"Richard":[558],"Schwab,":[559],"Edward":[560],"Cha,":[561],"Melinda":[562],"Telli.":[563],"Hormone":[565],"Receptor-Positive":[566],"Breast":[567,596],"Cancer:":[568],"Phase":[573],"Ib/II,":[574],"\u00b1":[578],"[abstract].":[588],"In:":[589],"Proceedings":[590],"2023":[593,599],"San":[594,602],"Antonio":[595],"Cancer":[597,608],"Symposium;":[598],"5-9;":[601],"Antonio,":[603],"TX.":[604],"Philadelphia":[605],"(PA):":[606],"AACR;":[607],"Res":[609],"2024;84(9":[610],"Suppl):Abstract":[611],"nr":[612],"PS12-08.":[613]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":6}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2024-05-03T00:00:00"}